
    
      Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the
      starting dose of talazoparib in combination with enzalutamide through assessment of target
      safety events and PK at select sites. Part 2 is a randomized, double-blind,
      placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo
      plus enzalutamide in patients with mCRPC.
    
  